Clinical Trials Logo
  1. Home
  2. Non-Alcoholic Steatohepatitis
  3. NCT01674972
  4. Details
NCT01674972 Clinical Trial

Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

Non Alcoholic Steatohepatitis Clinical Trial

Official title:
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01674972
Other study ID # EKBB 224/02.2
Secondary ID
Status Completed
Phase N/A
First received August 24, 2012
Last updated August 24, 2012
Start date January 2011
Est. completion date June 2012

Study information
Verified date August 2012
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Observational

Clinical Trial Summary

The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1 secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared to healthy controls. The results of this study will expand the knowledge of the pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.

Description:

Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge

Recruitment information / eligibility
Status Completed
Enrollment 102
Est. completion date June 2012
Est. primary completion date April 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Biopsy proven NAFLD or NASH

Exclusion Criteria:

- additional concomitants liver disease

- T2DM

- alcohol consumption >40g/d for male subjects and >20g/d for female subjects

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Other:
• Oral glucose tolerance test
Oral intake of 75 g glucose after overnight fast

Locations
Country Name City State
Switzerland University Hospital Basel, Division of Gastroenterology and Hepatology Basel

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Glucagon-like Peptide 1 (GLP-1) secretion in response to oGTT The difference in GLP-1 secretion in response to oGTT as assessed by area under the curve (AUC) and peak plasma concentration (cmax) in patients with NAFLD compared to healthy controls. 0, 15, 30, 60, 90, 120 min. after glucose administration No
Secondary Insulin secretion and glucose curves in response to oGTT 0, 15, 30, 60, 90, 120 min. after glucose administration No
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Completed NCT01695083 - Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Not yet recruiting NCT05605158 - Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis Phase 3
Completed NCT01761370 - Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH) N/A
Completed NCT03432377 - Coffee Consumption and NASH in the French Population.
Withdrawn NCT03864835 - NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal N/A
Completed NCT05357352 - Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Not yet recruiting NCT03803540 - Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis Phase 1
Completed NCT02395900 - The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Phase 2/Phase 3
Completed NCT01791959 - The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Phase 2/Phase 3
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT03734510 - The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study N/A
Recruiting NCT02721264 - Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis. N/A
Terminated NCT03883607 - Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) Phase 2
Completed NCT03863574 - Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT03377153 - The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT03377140 - The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease N/A
Active, not recruiting NCT04669158 - Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Phase 1/Phase 2
Recruiting NCT06176079 - Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease